Cartex H (candesartan cilexetil + hydrochlorothiazide): Uses, Dosage & Side Effects

What it's for (Indications)

Candesartan cilexetil combined with hydrochlorothiazide is indicated for the treatment of essential hypertension in adult patients.
This fixed-dose combination is particularly suitable for patients whose blood pressure is not adequately controlled with candesartan cilexetil or hydrochlorothiazide monotherapy, or for patients already receiving candesartan cilexetil and hydrochlorothiazide separately at the same dose levels.
By combining an angiotensin II receptor blocker (ARB) with a thiazide diuretic, this medication provides a synergistic effect, offering comprehensive control over elevated blood pressure and helping to reduce the risk of cardiovascular events associated with uncontrolled hypertension.
The decision to initiate this combination therapy should be based on an individual assessment of the patient's blood pressure response to monotherapy and their overall cardiovascular risk profile, aiming for optimal blood pressure targets as per clinical guidelines.

Dosage Information

Type	Guideline
Standard	The dosage of candesartan cilexetil and hydrochlorothiazide must be individualized based on the patient's blood pressure response and tolerability, typically administered once daily. The usual starting dose for patients not adequately controlled on monotherapy is often a lower combination strength, which can be titrated upwards if necessary, following a period of assessment (typically 2-4 weeks) to achieve the target blood pressure. It is generally recommended to take the medication at approximately the same time each day, with or without food, preferably in the morning. Dose adjustments should be made cautiously in patients with renal impairment, hepatic impairment, or volume depletion, as these conditions can alter the pharmacokinetics and pharmacodynamics of both components. Consultation of the full prescribing information for specific dose strengths and titration schedules is essential for healthcare professionals to ensure safe and effective use, avoiding any abrupt cessation.

Type

Guideline

Standard

The dosage of candesartan cilexetil and hydrochlorothiazide must be individualized based on the patient's blood pressure response and tolerability, typically administered once daily. The usual starting dose for patients not adequately controlled on monotherapy is often a lower combination strength, which can be titrated upwards if necessary, following a period of assessment (typically 2-4 weeks) to achieve the target blood pressure. It is generally recommended to take the medication at approximately the same time each day, with or without food, preferably in the morning. Dose adjustments should be made cautiously in patients with renal impairment, hepatic impairment, or volume depletion, as these conditions can alter the pharmacokinetics and pharmacodynamics of both components. Consultation of the full prescribing information for specific dose strengths and titration schedules is essential for healthcare professionals to ensure safe and effective use, avoiding any abrupt cessation.

Safety & Warnings

Common Side Effects

Patients taking candesartan cilexetil and hydrochlorothiazide may experience a range of side effects, though not everyone will.
Common side effects often include dizziness, lightheadedness, and fatigue, particularly at the initiation of therapy or with dose increases, primarily due to the blood pressure-lowering effect.
Headache and nausea are also frequently reported.
Due to the hydrochlorothiazide component, electrolyte imbalances such as hypokalemia (low potassium), hyponatremia (low sodium), hypomagnesemia (low magnesium), and hypercalcemia (high calcium) can occur, necessitating regular electrolyte monitoring.
Metabolic disturbances like hyperglycemia (elevated blood sugar) and hyperuricemia (elevated uric acid, potentially exacerbating gout) are also possible.
Less common but serious side effects associated with ARBs include renal dysfunction (worsening kidney function, especially in patients with pre-existing renal impairment or renal artery stenosis) and, rarely, angioedema, which manifests as swelling of the face, lips, tongue, or throat and requires immediate medical attention.
Photosensitivity, leading to increased sunburn risk, is also a known effect of thiazide diuretics.
Patients should report any persistent or severe side effects to their healthcare provider promptly.

Serious Warnings

Black Box Warning: Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue candesartan cilexetil + hydrochlorothiazide as soon as pregnancy is detected.
Candesartan cilexetil/hydrochlorothiazide is contraindicated in pregnant women, as it can cause fetal harm or death; pregnancy must be excluded before initiation and avoided during therapy.
It is also contraindicated in patients with anuria or hypersensitivity to any component of the product or to sulfonamide-derived drugs.
Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with an ARB, ACE inhibitor, or aliskiren is not recommended, especially in patients with diabetes or renal impairment, due to increased risk of hypotension, hyperkalemia, and renal function changes.
Caution is advised in patients with severe renal impairment (creatinine clearance <30 mL/min), hepatic impairment, or those with volume and/or sodium depletion, as these conditions may necessitate lower starting doses and careful monitoring.
Electrolyte disturbances (e.
g.
, hypokalemia, hyponatremia) require close monitoring.
There is an increased risk of symptomatic hypotension in volume-depleted patients.
Thiazide diuretics may exacerbate or activate systemic lupus erythematosus and may increase serum levels of lithium, requiring concurrent lithium monitoring.
Acute transient myopia and acute angle-closure glaucoma have been reported with hydrochlorothiazide, requiring immediate discontinuation.

How it Works (Mechanism of Action)

The therapeutic effect of candesartan cilexetil + hydrochlorothiazide stems from the complementary actions of its two active components. Candesartan cilexetil is a prodrug that is rapidly converted to candesartan, a selective angiotensin II type 1 (AT1) receptor blocker. By blocking the binding of angiotensin II to the AT1 receptor, candesartan inhibits the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to peripheral vasodilation, decreased systemic vascular resistance, and reduced sodium and water retention. This results in a significant reduction in blood pressure. Hydrochlorothiazide, a thiazide diuretic, acts primarily in the cortical diluting segment of the distal convoluted tubule of the nephron. It inhibits the Na+/Cl- cotransporter, thereby decreasing the reabsorption of sodium and chloride ions. This increased excretion of sodium, chloride, and accompanying water leads to a reduction in plasma volume and, consequently, a decrease in blood pressure. The combination provides an additive antihypertensive effect, with candesartan mitigating the potassium loss often associated with thiazide diuretics, while hydrochlorothiazide enhances the overall blood pressure reduction.